SELECT Trial
I completed my General Surgery training at the Hospital of the University of Pennsylvania and then specialized in Cardiothoracic Surgery at Columbia University Medical Center. Following his fellowship, I completed advanced training in Heart Failure and Heart/Lung Transplant Surgery at Columbia University and joined the... more
The weight loss injection, Semaglutide 2.4mg, has just been demonstrated to dramatically reduce the incidence of cardiovascular events in adults who are considered to be overweight or obese.
Once per week, subcutaneous, injection of Semaglutide (brand name Wegovy) reduced the risk of of cause cardiac events including CV Death, non-fatal Myocardial infarction, and nonfatal stroke).
The trial, which included 17,604 adults without history of diabetes, but who did have a history of cardiovascular disease and considered overweight or obese, were followed for five years in a trial called SELECT.
The results are the first to demonstrate that weight loss alone, is an independent predictor of improved cardiovascular survival.
